Xin Hua Cai Jing·2025-09-15 12:39Core Insights - The first and only approved stem cell drug in China, Aimi Maitosai Injection, has made significant progress with its first prescription issued in Beijing, marking the start of its commercial clinical application [1] - The drug, developed by domestic company Platinum Bio, is aimed at treating acute graft-versus-host disease (aGVHD) in patients over 14 years old who have failed hormone therapy [1] - The cost of Aimi Maitosai Injection is approximately 20,000 RMB per bag, significantly lower than similar products in the US, which are priced at 190,000 USD per bag, thus reducing the financial burden on patients [1] Product Development and Market Expansion - Aimi Maitosai Injection has transitioned the treatment of aGVHD from a single-target approach to a multi-target and multi-pathway treatment strategy [1] - The drug's service has achieved nationwide coverage in China, facilitated by strategic partner Alibaba Health, with appointment services available in over 20 provinces including Beijing, Shanghai, and Guangdong [1] - Ongoing research is being conducted to expand the drug's indications to include diabetic nephropathy, acute kidney injury, and vascular aging, potentially broadening its application in various disease areas [1]